| Autor: |
Folkestad L; Odense Universitetshospital, Endokrinologisk Afdeling M. Larsfolkestad@surfmail.dk, Bjerregaard JK, Bjarnason NH, Brixen KT |
| Jazyk: |
dánština |
| Zdroj: |
Ugeskrift for laeger [Ugeskr Laeger] 2007 May 07; Vol. 169 (19), pp. 1774-9. |
| Abstrakt: |
Aromatase inhibitors (AI) increase the disease-free survival of patients with receptor-positive breast cancer. They inhibit the endogenous production of estrogen by 50-90% and, in contrast to tamoxifen, reduce bone mineral density. Placebo-controlled studies have lacked statistical power to detect changes in fracture incidence; however, AI increases the incidence of fractures in comparison with tamoxifen. Therefore, we suggest that post-menopausal women starting on AI should be offered a DXA scan and that antiresorptive therapy should be considered for those with osteoporosis. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
